
Full text loading...
We use cookies to track usage and preferences.I Understand
In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.
This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.
All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.
Recombinant human IFN-γ proved high efficacy in multi-center clinical trials in routine TB practice.
The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis.
Article metrics loading...
Full text loading...
References
Data & Media loading...